Abstract: A mutated tryptophan oxidase suitable for practical implementation is described herein. Specifically, a mutated tryptophan oxidase wherein at least one amino acid residue of a wild-type tryptophan oxidase is mutated and, as a result, has higher tryptophan oxidase activity and/or stability as compared to the wild-type tryptophan oxidase. The mutated tryptophan oxidase can be derived from a wild-type tryptophan oxidase having at least one of Motifs (2), (3), (5), (7), (9), (11), (13), and (14), and at least one amino acid residue in any of these motifs can have mutation. The mutated tryptophan oxidase also can have a mutation of one or more amino acid residues in an amino acid sequence represented by SEQ ID NO: 2 and a sequence homologous thereto.

Abstract: The present disclosure provides engineered ketoreductase enzymes having improved properties as compared to a naturally occurring wild-type ketoreductase enzyme. Also provided are polynucleotides encoding the engineered ketoreductase enzymes, host cells capable of expressing the engineered ketoreductase enzymes, and methods of using the engineered ketoreductase enzymes to synthesize chiral compounds.

Abstract: The present disclosure relates to engineered ketoreductase polypeptides for the preparation of hydroxyl substituted carbamate compounds, and polynucleotides, vectors, host cells, and methods of making and using the ketoreductase polypeptides.

Abstract: The present invention provides a mutant beetle luciferase and the like, having mutation in which the amino acid corresponding to valine at position 288 in the amino acid sequence of wild-type Photinus pyralis luciferase is isoleucine, leucine or phenylalanine, mutation in which the amino acid corresponding to leucine at position 376 in the aforementioned sequence is proline, mutation in which the amino acid corresponding to glutamic acid at position 455 in the aforementioned sequence is valine, alanine, serine, leucine, isoleucine or phenylalanine, or mutation in which the amino acid corresponding to glutamic acid at position 488 in the aforementioned sequence is valine, alanine, serine, leucine, isoleucine or phenylalanine, in the amino acid sequence encoding a wild-type beetle luciferase, and characterized in that a luminescence intensity due to a luciferin-luciferase luminescence reaction in a 0.9% by mass NaCl solution is 50% or more of that in a NaCl-free solution.

Abstract: The subject invention concerns materials and methods for modulating seed size in plants. In one embodiment, seed size is decreased relative to wild type seed by inhibiting or knocking out expression of a sorbitol dehydrogenase (Sdh) gene or the gene product thereof. In another embodiment, seed size is increased relative to wild type seed by increasing expression of an Sdh gene or the gene product thereof. The subject invention also concerns materials and methods for modulating seed number or sugar content in plants. In one embodiment, seed number or sugar content is increased relative to wild type seed by inhibiting or knocking out expression of a sorbitol dehydrogenase (Sdh) gene or the gene product thereof. In another embodiment, seed number or sugar content is decreased relative to wild type seed by increasing expression of an Sdh gene or the gene product thereof.

Abstract: The present disclosure provides a culture device for enumerating colonies of sulfate-reducing microorganisms. The device includes a body having a waterproof base, a waterproof coversheet attached to the base, and a growth compartment disposed therebetween. The growth compartment has a perimeter and an opening. A portion of the perimeter is defined by a waterproof seal. The portion can include >50% of the perimeter. Disposed in the growth compartment are a dry cold water-soluble gelling agent, a dry culture medium selected to facilitate growth of a sulfate-reducing bacterium or indicator reagent for detecting hydrogen sulfide production by a sulfate-reducing bacterium, and a dry first oxygen-scavenging reagent.

Abstract: A microbial oil comprising dihomo-?-linolenic acid as a constituent fatty acid of an oil, the microbial oil has a content, in terms of a weight ratio of arachidonic acid relative to dihomo-?-linolenic acid (arachidonic acid/dihomo-?-linolenic acid) of less than 1/13. Preferably, the microbial oil has a triglyceride content of greater than or equal to 70% by weight, and a saturated fatty acid content of less than or equal to 40% by weight. Moreover, a lower alcohol ester of dihomo-?-linolenic acid or a free fatty acid of dihomo-?-linolenic acid obtained from the microbial oil is provided.

Abstract: The present invention relates to a Bacillus amyloliquefaciens strain that produces superoxide dismutase (SOD), and also relates to an antioxidant, anti-inflammatory pharmaceutical composition and a pharmaceutical composition and food composition for preventing or treating hyperlipidemia, which include a superoxide dismutase produced by the Bacillus amyloliquefaciens strain. The compositions of the present invention exhibit excellent effects without causing side effects, and may thus be used as functional raw materials or products having an enhanced activity of preventing or treating inflammation, cancer or hyperlipidemia in the pharmaceutical drug, food, cosmetic and livestock fields.

Abstract: The present disclosure relates to the biosynthesis of indigoid dye precursors and their conversion to indigoid dyes. Specifically, the present disclosure relates to methods of using polypeptides to produce indigoid dye precursors from indole feed compounds, and the use of the indigoid dye precursors to produce indigoid dyes.

Abstract: An ex vivo method and a kit for predicting the response to a treatment with glucocorticoids (GC) in patients affected by inflammatory diseases, based on quantification of fold change ratio in GR isoform levels.

Abstract: The present disclosure relates to polypeptides having transaminase activity, polynucleotides encoding the polypeptides, and methods of using the polypeptides.

Abstract: The present invention provides host cells for use in an inducible coexpression system that is capable of controlled induction of expression of each gene product.

Abstract: The disclosure relates to engineered ketoreductase polypeptides and processes of using the polypeptides for production of phenylephrine.

Abstract: This invention provides recombinant DNA constructs, transgenic plant nuclei and cells with such recombinant DNA construct for expression of proteins that are useful for imparting enhanced agronomic trait(s) to transgenic crop plants. This invention also provides transgenic plants and progeny seed comprising the transgenic plant cells where the plants are selected for having an enhanced trait selected from the group of traits consisting of enhanced water use efficiency, enhanced cold tolerance, increased yield, enhanced nitrogen use efficiency, enhanced seed protein and enhanced seed oil. Also disclosed are methods for manufacturing transgenic seed and plants with enhanced traits.

Abstract: The present disclosure relates to a multi-enzyme conjugate, a method for preparing the same and a method for preparing an organic compound using the same. More particularly, a multi-enzyme conjugate exhibiting improved catalytic efficiency over respective free enzymes using site-specific incorporation of a clickable non-natural amino acid into the enzymes and two compatible click reactions, a method for preparing the same and a method for preparing an organic compound using the same may be provided.

Abstract: The present disclosure relates to non-naturally occurring polypeptides useful for preparing Ezetimibe, polynucleotides encoding the polypeptides, and methods of using the polypeptides.

Abstract: The present invention relates to a process for the production of squalene and/or sterol in high amounts using an alkaline solution and an organic lysis solvent at high temperature and high pressure for effectively lysing yeast cells and extracting squalene and/or sterol into an organic extraction solvent, thus obtaining squalene and/or sterolin high amount and of high purity.

Abstract: An object of the present invention is to provide a novel method capable of producing rosuvastatin calcium and intermediates therefor efficiently, inexpensively and with high purity. The present invention provides a method of efficiently producing rosuvastatin calcium and intermediates therefor having a high purity at an industrial scale, without using an extremely low temperature reaction or a special asymmetric catalyst.

Abstract: The invention relates to biotechnology and provides novel recombinant DNA molecules and engineered proteins for conferring tolerance to protoporphyrinogen oxidase-inhibitor herbicides. The invention also provides herbicide tolerant transgenic plants, seeds, cells, and plant parts containing the recombinant DNA molecules, as well as methods of using the same.

Abstract: The invention relates to biotechnology and provides novel recombinant DNA molecules and engineered proteins for conferring tolerance to protoporphyrinogen oxidase-inhibitor herbicides. The invention also provides herbicide tolerant transgenic plants, seeds, cells, and plant parts containing the recombinant DNA molecules, as well as methods of using the same.

Abstract: The disclosure relates to engineered ketoreductase polypeptides and processes of using the polypeptides for production of phenylephrine.

Abstract: The invention relates to fusarium toxin-cleaving polypeptide variants of a fusarium toxin carboxyl esterase with the SEQ ID NO:46. Each of the polypeptide variants has an amino acid sequence shortened by 47 amino acids at the N terminus, and the amino acid sequences have at least 70%, preferably 80%, in particular 100%, sequence identity, namely SEQ ID NO:1, to the amino acid sequence portion 48-540 of the SEQ ID NO:46. The invention also relates to isolated polynucleotides which code for the polypeptide variants, to a fusarium toxin-cleaving additive containing at least one polypeptide variant and optionally at least one auxiliary agent, to the use of the polypeptide variants or the additive, and to a method for hydrolytically cleaving at least one fusarium toxin.

Abstract: The present disclosure relates to engineered ketoreductase polypeptides for the preparation of hydroxyl substituted carbamate compounds, and polynucleotides, vectors, host cells, and methods of making and using the ketoreductase polypeptides.

Abstract: The present disclosure provides engineered ketoreductase enzymes having improved properties as compared to a naturally occurring wild-type ketoreductase enzyme including the capability of reducing 5-((4S)-2-oxo-4-phenyl (1,3-oxazolidin-3-yl))-1-(4-fluorophenyl) pentane-1,5-dione to (4S)-3-[(5S)-5-(4-fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-1,3-oxazolidin-2-one. Also provided are polynucleotides encoding the engineered ketoreductase enzymes, host cells capable of expressing the engineered ketoreductase enzymes, and methods of using the engineered ketoreductase enzymes to synthesize the intermediate (4S)-3-[(5S)-5-(4-fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-1,3-oxazolidin-2-one in a process for making Ezetimibe.

Abstract: The present disclosure pertains to methods of producing recombinant peptides that contain between 10 and 200 amino acid residues using novel carrier proteins derived from superfolder green fluorescent protein and its mutants.

Abstract: An object of the present invention is to provide enzymes and a DNA encoding the enzymes that are involved in biosynthesis of trehangelin which has the potential to be a therapeutic agent for photosensitivity disorder and cosmetics, and to provide a method for producing trehangelin by utilizing the enzymes and a recombinant microorganism. The present invention is directed to a protein having an amino acid sequence of SEQ ID NO: 3, 5, 7 or 9, or a protein having an amino acid sequence of SEQ ID NO: 3, 5, 7 or 9 in which one to several amino acids are deleted, substituted, added and/or inserted or an amino acid sequence having 60% or more homology with the amino acid sequence of SEQ ID NO: 3, 5, 7 or 9 and having an enzyme activity involved in biosynthesis of trehangelin; and a DNA encoding said protein.

Abstract: Improved matrix or hydrogel that is formed by enzymatic crosslinking of polymers wherein the crosslinking enzyme molecules have been modified for the purpose of improving the crosslinking density, mechanical properties, or other properties of the matrix, and/or to provide improved control over the rate and/or extent of crosslinking, wherein the enzyme molecules are modified to alter the perceived volume of the enzyme molecules in the crosslinked matrix being formed. Methods of production and of use are also provided.

Abstract: A novel luciferase that distinct from conventional luciferase has been desired. A luciferase mutant comprising the amino acid sequence of SEQ ID NO: 2 substituted at tyrosine at the position of 138, and at least 3 positions selected from the group consisting of isoleucine at the position of 90, proline at the position of 115, glutamine at the position of 124, and asparagine at the position of 166.

Abstract: The present disclosure relates to engineered ketoreductase polypeptides for the preparation of hydroxyl substituted carbamate compounds, and polynucleotides, vectors, host cells, and methods of making and using the ketoreductase polypeptides.

Abstract: The invention relates to ketoreductases and the use thereof. The ketoreductases of the invention are particularly useful for enzymatically catalyzing the reduction of ketones to chiral secondary alcohols.

Abstract: The present disclosure relates to non-naturally occurring polypeptides useful for preparing Ezetimibe, polynucleotides encoding the polypeptides, and methods of using the polypeptides.

Abstract: The present disclosure provides engineered ketoreductase enzymes having improved properties as compared to a naturally occurring wild-type ketoreductase enzyme including the capability of reducing 5-((4S)-2-oxo-4-phenyl (1,3-oxazolidin-3-yl))-1-(4-fluorophenyl) pentane-1,5-dione to (4S)-3-[(5S)-5-(4-fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-1,3-oxazolidin-2-one. Also provided are polynucleotides encoding the engineered ketoreductase enzymes, host cells capable of expressing the engineered ketoreductase enzymes, and methods of using the engineered ketoreductase enzymes to synthesize the intermediate (4S)-3-[(5S)-5-(4-fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-1,3-oxazolidin-2-one in a process for making Ezetimibe.

Abstract: Fructosyl amino acid oxidase is provided, which has an amino acid sequence as shown in SEQID. No. 1 or fructosyl amino acid oxidase having a homology of more than 80% with this amino acid sequence, on a corresponding site of an amino acid selected from following (a) to (f), having one or more amino acid residues conducting a substitution, obtained fructosyl amino acid oxidase having a higher thermostability: (a) 59-site glutamic acid, (b) 98-site glutamic acid, (c) 225-site glycine, (d) 277-site lysine, (e) 285-site glutamic acid, and (f) 355-site aspartic acid. The method for preparing the above oxidase and the test kit containing the enzyme for determining glycated albumin are also provided.

Abstract: The present invention relates to a method for producing a protein of interest containing one or more disulfide bonds in its native state. The method comprises that a prokaryotic host cell is genetically engineered to express the protein of interest and a sulfhydryl oxidase in the cytoplasm of the host cell. The protein of interest is formed in a soluble form and contains disulfide bonds due to the presence of the sulfhydryl oxidase in the cytoplasm of said host cell. The present invention relates also to a prokaryotic host cell and a vector system for producing a protein of interest containing natively folded disulfide bonds.

Abstract: This invention relates to modified hydroxylases. The invention further relates to cells expressing such modified hydroxylases and methods of producing hydroxylated alkanes by contacting a suitable substrate with such cells.

Abstract: An isolated peptide or fusion having the peptide useful to interfere with the phosphorylation of Nox1, block or inhibit binding of NoxA1 activation domain (AD) to Nox1, and/or prevent or inhibit assembly of the p47phox/NoxA1 complex with Nox1, or a vector encoding the peptide or fusion thereof, and methods of using the peptide, fusion or vector are provided.

Abstract: Described herein are variants of H. jecorina CBH I, a Cel7 enzyme. The present invention provides novel cellobiohydrolases that have improved thermostability and reversibility.

Abstract: A novel luciferase that is distinct from conventional luciferase has been desired. A luciferase mutant comprising an amino acid sequence in which glutamic acid at position 4, arginine at position 11, leucine at position 18 and valine at position 27 are substituted with other amino acids, in the amino acid sequence of SEQ ID NO: 2.

Abstract: One embodiment described herein is related to methods and compositions, such as nutraceutical formulations and dietary supplements, comprising C16:1n7-palmitoleate or derivatives thereof. The methods and compositions comprising C16:1n7-palmitoleate, or derivatives thereof, safely and effectively prevent or mitigate manifestations of cardiovascular disease, including coronary artery disease and the accumulation of cholesterol or lipid deposits in the blood vessels of a subject.

Abstract: Methods for the production of L-glufosinate (also known as phosphinothricin or (S)-2-amino-4-(hydroxy(methyl)phosphonoyl)butanoic acid) are provided. The methods comprise a two-step process. The first step involves the oxidative deamination of D-glufosinate to PPO (2-oxo-4-(hydroxy(methyl)phosphinoyl)butyric acid). The second step involves the specific amination of PPO to L-glufosinate, using an amine group from one or more amine donors. By combining these two reactions, the proportion of L-glufosinate in a mixture of L-glufosinate and D-glufosinate can be substantially increased.

Abstract: The present invention provides a stable cell line overexpressing a recombinant vitamin K-dependent (VKD) protein and both a recombinant vitamin K epoxide reductase (VKOR) and a recombinant vitamin K dependent gamma carboxylase (VKGC), wherein the amount of fully carboxylated VKD protein produced in the cell is increased 10% as compared to the amount of fully carboxylated VKD protein produced in the cell in the absence of the recombinant VKOR and the recombinant VKGC.

Abstract: A microbial oil comprising dihomo-?-linolenic acid as a constituent fatty acid of an oil, the microbial oil has a content, in terms of a weight ratio of arachidonic acid relative to dihomo-?-linolenic acid (arachidonic acid/dihomo-?-linolenic acid) of less than 1/13. Preferably, the microbial oil has a triglyceride content of greater than or equal to 70% by weight, and a saturated fatty acid content of less than or equal to 40% by weight. Moreover, a lower alcohol ester of dihomo-?-linolenic acid or a free fatty acid of dihomo-?-linolenic acid obtained from the microbial oil is provided.

Abstract: A method of detecting and quantifying various enzymatic activities using a constructed artificial genetic circuit GESS (genetic enzyme screening system) for sensing phenolic compounds and a method of screening a trace of activities of target enzymes from a metagenome using the artificial genetic circuit, thereby securing target enzyme genes. When the method for screening and quantifying target enzymatic activity is used, useful genes can be screened from various genetic communities, including environmental or metagenomic libraries, at a single cell level in high throughput (million/day). Further, the sensitivity of the genetic circuit to phenol derivatives and the expression thereof can be controlled, and thus the genetic circuit can rapidly sense and quantify various enzymatic activities. Thus, the method can be advantageously used in the protein engineering technology for enzyme modification.

Abstract: The present invention relates to polypeptides having cellulolytic enhancing activity, catalytic domains, and carbohydrate binding domains, and polynucleotides encoding the polypeptides, catalytic domains, and carbohydrate binding domains. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides, catalytic domains, and carbohydrate binding domains.

Abstract: The present invention encompasses modified luciferases, methods for making modified luciferases, and assays utilizing modified luciferases. Modified luciferases of the invention show increased activity over wildtype luciferases and also show increased stability of signal. The present invention also encompasses multiplex assays utilizing multiple luciferases with different emission spectra.

Abstract: The present invention provides use of a plant gene JAZ5a for improving drought-resistance of a plant. It further provides a method for improving the drought-resistance of a plant, comprising enhancing the expression or activity of Jaz5A in said plant.

Abstract: The present invention relates to recombinant Trichoderma host cells producing Aspergillus fumigatus cellulolytic enzyme compositions and methods of producing and using the compositions.

Abstract: The invention relates to a process for the production of 4-aminobutyric acid, also referred to as gamma-aminobutyric acid, in short GABA, to a process for the production of an extract comprising 4-aminobutyric acid, to a process for the preparation of a cosmetic formulation comprising 4-aminobutyric acid, and to the use of Cyanidium caldarium cells or cell components in cosmetic applications.

Abstract: A pectinase having improved thermostability is disclosed. The pectinase has a modified amino acid sequence of SEQ ID NO: 2, wherein the modification is a substitution of serine at position 181 with phenylalanine, methionine or leucine.

Abstract: The present disclosure relates to non-naturally occurring polypeptides useful for preparing Ezetimibe, polynucleotides encoding the polypeptides, and methods of using the polypeptides.